8-K Announcements
6Material company update
Mar 3, 2026·SEC
Material company update
Jan 7, 2026·SEC
Material company update
Dec 11, 2025·SEC
Enliven Therapeutics, Inc.(ELVN)Earnings, Financials & Key Ratios
ELVN•NASDAQ
$41.20
$2.45B mkt cap·Price updated May 6, 2026
AboutEnliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.Show more
- Revenue$0
- EBITDA-$119M-14.5%
- Net Income-$104M-16.5%
- EPS (Diluted)-1.83+3.2%
- ROE-26.95%+15.9%
- ROIC-32.85%+30.5%
ELVN Key Insights
Enliven Therapeutics, Inc. (ELVN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 95 (top 5%)
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Shares diluted 20.4% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ELVN Price & Volume
Enliven Therapeutics, Inc. (ELVN) stock price & volume — 10-year historical chart
Loading chart...
ELVN Growth Metrics
Enliven Therapeutics, Inc. (ELVN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-16.48%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM3.17%
Return on Capital
10 Years-64.28%
5 Years-37.92%
3 Years-40.33%
Last Year-31.1%
ELVN Recent Earnings
Enliven Therapeutics, Inc. (ELVN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)
Q2 2026Latest
Mar 3, 2026EPS
$0.48
Est $0.42
-14.3%
Revenue
—
Est $12,500
Q4 2025
Nov 12, 2025EPS
$0.32
Est $0.43
+25.6%
Revenue
—
Est $8,330
Q3 2025
Aug 13, 2025EPS
$0.49
Est $0.53
+7.5%
Revenue
—
Q2 2025
May 14, 2025EPS
$0.57
Est $0.51
-11.8%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 3, 2026 | $0.48vs $0.42-14.3% | —vs $12,500 |
| Q4 2025 | Nov 12, 2025 | $0.32vs $0.43+25.6% | —vs $8,330 |
| Q3 2025 | Aug 13, 2025 | $0.49vs $0.53+7.5% | — |
| Q2 2025 | May 14, 2025 | $0.57vs $0.51-11.8% | — |
Based on last 12 quarters of dataView full earnings history →
ELVN Peer Comparison
Enliven Therapeutics, Inc. (ELVN) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 KYMR | 7.04B | 86.26 | -23.38 | -16.72% | -6.12% | -25.02% | 0.05 | |
 RVMD | 32.12B | 151.07 | -25.39 | -83.22% | 0.10 | |||
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 AUPH | 2.15B | 16.25 | 7.85 | 20.38% | 101.47% | 49.4% | 0.13 | |
 PRAX | 7.61B | 337.95 | -25.07 | -100% | -58.74% | 0.00 | ||
 ARQT | 3.02B | 24.17 | -185.92 | 91.34% | -0.57% | -1.41% | 0.03 | |
 MGNX | 190.59M | 3.01 | -2.55 | 0.78% | -49.91% | -120.2% | 0.66 | |
 PTCT | 5.52B | 66.61 | 8.56 | 114.51% | 39.44% |
Compare ELVN vs Peers
Enliven Therapeutics, Inc. (ELVN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ELVN Income Statement
Enliven Therapeutics, Inc. (ELVN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 33K | 0 | 0 | 0 | 0 | 0 | 263K |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | -33K▲ 0% | 0▲ 100.0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -263K▲ 0% |
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | 100% | - | - | - | - | - |
| Operating Expenses | 8.9M | 10.68M | 24.08M | 9.32M | 24.76M | 38.79M | 83.53M | 104.55M | 119.39M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 987K | 2.44M | 5.07M | 1.08M | 4.29M | 7.77M | 18.95M | 23.78M | 33.8M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - |
| Research & Development | 7.92M | 8.24M | 19.01M | 8.24M | 20.47M | 31.02M | 64.57M | 80.78M | 85.86M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -8.9M▲ 0% | -10.68M▼ 19.9% | -24.12M▼ 125.9% | -9.32M▲ 61.4% | -24.76M▼ 165.7% | -38.79M▼ 56.7% | -83.53M▼ 115.3% | -104.55M▼ 25.2% | -119.66M▼ 14.4% |
| Operating Margin % | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -19.9% | -125.87% | 61.36% | -165.74% | -56.66% | -115.33% | -25.17% | -14.45% |
| EBITDA | 221K | -11.34M | -24.08M | -9.27M | -24.65M | -38.58M | -83.23M | -104.24M | -119.39M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | - | -5229.86% | -112.43% | 61.5% | -165.79% | -56.51% | -115.76% | -25.24% | -14.54% |
| D&A (Non-Cash Add-back) | 0 | -660K | 33K | 45K | 115K | 215K | 297K | 317K | 263K |
| EBIT | 221K | -11.34M | -23.46M | -9.32M | -24.76M | -38.79M | -83.53M | -104.55M | -119.66M |
| Net Interest Income | 0 | 0 | 578K | 483K | 22K | 1.13M | 11.97M | 14.89M | 16.01M |
| Interest Income | 0 | 0 | 578K | 483K | 22K | 1.13M | 11.97M | 14.89M | 16.01M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 9.13M | -660K | 653K | -9.65M | 22K | 1.13M | 11.95M | 15.76M | 15.96M |
| Pretax Income | 221K▲ 0% | -11.34M▼ 5229.9% | -23.46M▼ 107.0% | -18.97M▲ 19.2% | -24.74M▼ 30.4% | -37.66M▼ 52.2% | -71.58M▼ 90.1% | -88.79M▼ 24.0% | -103.69M▼ 16.8% |
| Pretax Margin % | - | - | - | - | - | - | - | - | - |
| Income Tax | 221K | 0 | 0 | 0 | 0 | 0 | 0 | 232K | 0 |
| Effective Tax Rate % | 100% | 0% | 0% | 0% | 0% | 0% | 0% | -0.26% | 0% |
| Net Income | 0▲ 0% | -11.34M▲ 0% | -23.46M▼ 107.0% | -18.97M▲ 19.2% | -24.74M▼ 30.4% | -37.66M▼ 52.2% | -71.58M▼ 90.1% | -89.02M▼ 24.4% | -103.69M▼ 16.5% |
| Net Margin % | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | - | - | -106.96% | 19.17% | -30.44% | -52.23% | -90.07% | -24.36% | -16.48% |
| Net Income (Continuing) | 221K | -11.34M | -23.46M | -18.97M | -24.74M | -37.66M | -71.58M | -89.02M | -103.69M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 0.00▲ 0% | -2.62▲ 0% | -5.43▼ 107.3% | -4.31▲ 20.6% | -3.17▲ 26.5% | -6.03▼ 90.2% | -2.01▲ 66.7% | -1.89▲ 6.0% | -1.83▲ 3.2% |
| EPS Growth % | - | - | -107.25% | 20.63% | 26.45% | -90.22% | 66.67% | 5.97% | 3.17% |
| EPS (Basic) | 0.00 | -2.62 | -5.43 | -4.31 | -3.17 | -6.03 | -2.01 | -1.89 | -1.83 |
| Diluted Shares Outstanding | 4.32M | 4.32M | 4.32M | 4.39M | 7.82M | 6.25M | 35.55M | 47.07M | 56.66M |
| Basic Shares Outstanding | 4.32M | 4.32M | 4.32M | 4.39M | 7.81M | 6.25M | 35.55M | 47.07M | 56.66M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
ELVN Balance Sheet
Enliven Therapeutics, Inc. (ELVN) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 10.22M | 7.71M | 30.62M | 90.41M | 110.67M | 77.75M | 266.15M | 318.13M | 474.88M |
| Cash & Short-Term Investments | 9.67M | 7.38M | 28.91M | 88.22M | 110.02M | 75.54M | 253.15M | 313.44M | 462.62M |
| Cash Only | 9.67M | 7.38M | 4.94M | 47.7M | 110.02M | 75.54M | 100.14M | 124.12M | 98.9M |
| Short-Term Investments | 0 | 0 | 23.97M | 40.52M | 0 | 0 | 153.01M | 189.32M | 363.73M |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 552K | 323K | 1.72M | 2.18M | 0 | 2.22M | 10.05M | 4.69M | 12.26M |
| Total Non-Current Assets | 0 | 0 | 2.67M | 437K | 2.66M | 5.54M | 5.72M | 7.63M | 1.29M |
| Property, Plant & Equipment | 0 | 0 | 442K | 349K | 954K | 1.52M | 1.06M | 458K | 417K |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 88K | 0 | 0 | 54K | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 2.14M | 88K | 1.71M | 3.98M | 4.65M | 7.17M | 873K |
| Total Assets | 10.22M▲ 0% | 7.71M▼ 24.6% | 33.3M▲ 332.2% | 90.84M▲ 172.8% | 113.33M▲ 24.8% | 83.3M▼ 26.5% | 271.87M▲ 226.4% | 325.76M▲ 19.8% | 476.17M▲ 46.2% |
| Asset Turnover | - | - | - | - | - | - | - | - | - |
| Asset Growth % | - | -24.63% | 332.16% | 172.82% | 24.75% | -26.5% | 226.38% | 19.82% | 46.17% |
| Total Current Liabilities | 826K | 1.83M | 4.2M | 6.25M | 5.75M | 9.71M | 25.89M | 15.91M | 16.57M |
| Accounts Payable | 431K | 908K | 1.66M | 1.97M | 2.52M | 3.44M | 532K | 1.34M | 2.16M |
| Days Payables Outstanding | - | - | 18.34K | - | - | - | - | - | 3K |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 5.51M | 0 | 0 | 0 |
| Other Current Liabilities | 196K | 787K | 1.74M | 3.19M | 233K | 320K | 10.36M | 204K | 16.57M |
| Current Ratio | 12.38x | 4.21x | 7.29x | 14.47x | 19.24x | 8.00x | 10.28x | 19.99x | 28.66x |
| Quick Ratio | 12.38x | 4.21x | 7.29x | 14.47x | 19.24x | 8.00x | 10.28x | 19.99x | 28.66x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 660K | 32.19M | 184K | 160K | 714K | 150.41M | 67K | 0 | 0 |
| Long-Term Debt | 660K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 32.19M | 184K | 160K | 714K | 150.41M | 67K | 0 | 0 |
| Total Liabilities | 1.49M | 1.83M | 4.38M | 6.41M | 6.47M | 160.12M | 25.96M | 15.91M | 16.57M |
| Total Debt | 660K | 0 | 0 | 0 | 159K | 323K | 335K | 0 | 0 |
| Net Debt | -9.01M | -7.38M | -4.94M | -47.7M | -109.86M | -75.21M | -99.81M | -124.12M | -98.9M |
| Debt / Equity | - | - | - | - | 0.00x | - | 0.00x | - | - |
| Debt / EBITDA | 2.99x | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | -40.77x | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | - | - | - |
| Total Equity | -15.53M▲ 0% | -26.32M▼ 69.4% | 28.92M▲ 209.9% | 84.44M▲ 192.0% | 106.86M▲ 26.6% | -76.83M▼ 171.9% | 245.91M▲ 420.1% | 309.85M▲ 26.0% | 459.6M▲ 48.3% |
| Equity Growth % | - | -69.41% | 209.88% | 192% | 26.56% | -171.89% | 420.09% | 26% | 48.33% |
| Book Value per Share | -3.60 | -6.09 | 6.69 | 19.23 | 13.67 | -12.29 | 6.92 | 6.58 | 8.11 |
| Total Shareholders' Equity | -15.53M | -26.32M | -48.85M | 84.44M | 106.86M | -76.83M | 245.91M | 309.85M | 459.6M |
| Common Stock | 4K | 4K | 4K | 18K | 1K | 1K | 41K | 49K | 59K |
| Retained Earnings | -19.95M | -31.29M | -54.75M | -96.11M | -45.2M | -82.86M | -154.45M | -243.47M | -347.17M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 32K | 4K | 0 | -149.75K | 141K | 55K | 334K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ELVN Cash Flow Statement
Enliven Therapeutics, Inc. (ELVN) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -8.79M | -8.78M | -21.88M | -8.53M | -19.13M | -32.08M | -61.27M | -73.19M | -70.3M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - |
| Operating CF Growth % | - | 0.09% | -149.25% | 61.01% | -124.34% | -67.64% | -91.01% | -19.46% | 3.95% |
| Net Income | 0 | -11.34M | -23.46M | -18.97M | -24.74M | -37.66M | -71.58M | -89.02M | -103.69M |
| Depreciation & Amortization | 0 | 0 | 33K | 45K | 115K | 215K | 297K | 317K | 36K |
| Stock-Based Compensation | 0 | 555K | 899K | 130K | 1.92M | 3.19M | 12.91M | 20.17M | 34.02M |
| Deferred Taxes | 0 | 0 | -215K | 0 | -3.81M | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -7.93M | 848K | 196K | 9.68M | 3.81M | 1.74M | -4.3M | -118K | -662K |
| Working Capital Changes | -188K | 1.24M | 673K | 583K | 3.57M | 438K | 1.4M | -4.54M | 0 |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -666K | 477K | 750K | 291K | 1.73M | 411K | -2.25M | 810K | 817K |
| Cash from Investing | 0 | 0 | -24.06M | -461K | -191K | -612K | -148.41M | -36M | -173.84M |
| Capital Expenditures | 0 | 0 | -140K | -461K | -191K | -612K | -149K | -44K | -158K |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 35M | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 16.7M | 1.62M | -41.88M | 0 | 873K | 213K |
| Cash from Financing | 11M | 6.49M | 43.58M | 130.51M | -1.02M | -1.8M | 234.29M | 133.16M | 218.87M |
| Debt Issued (Net) | 0 | 0 | -2M | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 0 | 0 | 1000K | 1000K | -1000K | -1000K | 1000K | 1000K | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 620K |
| Other Financing | 11M | 6.49M | 0 | 33.63M | 0 | -566K | 73.08M | 93.98M | 218.87M |
| Net Change in Cash | 2.21M▲ 0% | -2.29M▼ 203.3% | -2.45M▼ 6.9% | 121.52M▲ 5068.2% | -20.34M▼ 116.7% | -34.49M▼ 69.5% | 24.61M▲ 171.3% | 23.98M▼ 2.6% | -25.27M▼ 205.4% |
| Free Cash Flow | -8.79M▲ 0% | -8.78M▲ 0.1% | -22.02M▼ 150.8% | -8.99M▲ 59.2% | -19.32M▼ 115.0% | -32.69M▼ 69.2% | -61.42M▼ 87.9% | -73.24M▼ 19.2% | -70.46M▲ 3.8% |
| FCF Margin % | - | - | - | - | - | - | - | - | - |
| FCF Growth % | - | 0.09% | -150.85% | 59.17% | -114.96% | -69.15% | -87.89% | -19.24% | 3.79% |
| FCF per Share | -2.03 | -2.03 | -5.10 | -2.05 | -2.47 | -5.23 | -1.73 | -1.56 | -1.24 |
| FCF Conversion (FCF/Net Income) | - | 0.77x | 0.93x | 0.45x | 0.77x | 0.85x | 0.86x | 0.82x | 0.68x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 232K | 0 |
ELVN Key Ratios
Enliven Therapeutics, Inc. (ELVN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -1804.85% | -33.46% | -25.87% | -250.77% | -84.67% | -32.04% | -26.95% |
| Return on Invested Capital (ROIC) | - | - | - | -23.02% | -110.11% | - | - | -47.26% | -32.85% |
| Debt / Equity | - | - | - | - | 0.00x | - | 0.00x | - | - |
| FCF Conversion | - | 0.77x | 0.93x | 0.45x | 0.77x | 0.85x | 0.86x | 0.82x | 0.68x |
ELVN SEC Filings & Documents
Enliven Therapeutics, Inc. (ELVN) SEC filings — annual & quarterly reports (10-K, 10-Q)
ELVN Frequently Asked Questions
Enliven Therapeutics, Inc. (ELVN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Enliven Therapeutics, Inc. (ELVN) grew revenue by 0.0% over the past year. Growth has been modest.
Enliven Therapeutics, Inc. (ELVN) reported a net loss of $103.7M for fiscal year 2025.
Dividend & Returns
Enliven Therapeutics, Inc. (ELVN) has a return on equity (ROE) of -27.0%. Negative ROE indicates the company is unprofitable.
Enliven Therapeutics, Inc. (ELVN) had negative free cash flow of $70.5M in fiscal year 2025, likely due to heavy capital investments.
Explore More ELVN
Enliven Therapeutics, Inc. (ELVN) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates